LOGIN  |  REGISTER

Rocket Pharmaceuticals (NASDAQ: RCKT) Stock Quote

Last Trade: US$21.86 -1.00 -4.37
Volume: 417,434
5-Day Change: -4.92%
YTD Change: -27.06%
Market Cap: US$1.980B

Latest News From Rocket Pharmaceuticals

CRANBURY, N.J. / May 29, 2024 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has... Read More
Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global RP-L102 Fanconi Anemia Phase 1/2 trial demonstrate genetic and phenotypic correction combined with hematologic stabilization extending to 42... Read More
Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio beginning with KRESLADI™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of June 30, 2024 Appointed Aaron Ondrey as Chief Financial Officer, bringing seasoned leadership experience in commercial-stage financial management,... Read More
Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after treatment with RP-L102 CRANBURY, N.J. / Apr 02, 2024 / Business Wire / Rocket Pharmaceuticals, Inc . (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare... Read More
Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key appointments within existing corporate leadership team expand capabilities and expertise spanning early discovery through commercialization CRANBURY, N.J. / Mar 26, 2024 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a... Read More
Advancing leading pipeline of six disclosed programs across AAV cardiovascular and LV hematology portfolios; all milestones remain on track for 2024 Expanding commercial capabilities to support launch of LV portfolio beginning with KRESLADI ™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of June 30, 2024 Cash, cash equivalents and investments of approximately $407.5M; expected operational runway into 2026... Read More
New Prescription Drug User Fee Act (PDUFA) date of June 30, 2024 CRANBURY, N.J. / Feb 13, 2024 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the U.S. Food and Drug Administration (FDA) has extended the Priority Review period for the Biologics... Read More
CRANBURY, N.J. / Jan 02, 2024 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:45 p.m. PT.... Read More
CRANBURY, N.J. / Dec 12, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors. Mr. Woods is a seasoned executive with more than 30 years of... Read More
Agreement reached with FDA on Phase 2 pivotal study design of RP-L301 for PKD to support accelerated approval; Initiating single-arm, 10-patient pivotal study with primary endpoint of ≥1.5 point Hgb improvement at 12 months Initiated Phase 2 pivotal trial of RP-A501 for Danon Disease following FDA alignment Initiated Phase 1 study of RP-A601 for PKP2-ACM FDA accepted BLA with Priority Review for KRESLADI TM (marnetegragene... Read More
CRANBURY, N.J. / Oct 19, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced presentations at the 30 th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in Brussels, Belgium, taking place October 24-27. Updated data will... Read More
Prescription Drug User Fee Act (PDUFA) target action date is March 31, 2024 RP-L201 has received FDA Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track and Orphan Drug designations; Rocket eligible for Priority Review Voucher, if RP-L201 is approved CRANBURY, N.J. / Oct 02, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an... Read More
CRANBURY, N.J. / Sep 26, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a fireside chat at the Chardan 7 th Annual Genetic Medicines Conference in New York... Read More
CRANBURY, N.J. / Sep 13, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today the pricing of an underwritten public offering of (i) 7,812,500 shares of its common stock at a public offering price of $16.00 per share... Read More
Final alignment reached on a 12 patient, single-arm, open label study with a biomarker based co-primary endpoint assessed at 12 months to support accelerated approval Co-primary endpoint consisting of LAMP2 protein expression and Left Ventricular (LV) Mass change from baseline CRANBURY, N.J. / Sep 12, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an... Read More
CRANBURY, N.J. / Sep 12, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high unmet need, announced today that it intends to offer and sell shares of its common stock, and to certain investors, pre-funded warrants to purchase shares of its... Read More
CRANBURY, N.J. / Sep 06, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Company management will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference and Cantor Fitzgerald Global Healthcare Conference 2023.... Read More
Initiating enrollment of two-patient pediatric safety run-in for pivotal single-arm Phase 2 study of RP-A501 (Danon Disease); finalizing primary composite endpoint with FDA to support accelerated approval RP-L201 (LAD-I) BLA submitted to FDA; represents Rocket’s first product filing RP-A601 (PKP2-ACM) advancing towards first patient treatment in Phase 1 study following FDA clearance of IND; received FDA Fast Track and Orphan... Read More
CRANBURY, N.J. / Jun 08, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to RP-A601, the Company’s gene therapy candidate for the... Read More
CRANBURY, N.J. / May 31, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501, the Company’s investigational adeno-associated virus... Read More
CRANBURY, N.J. / May 23, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the Company’s investigational... Read More
Robust and sustained efficacy in both adult PKD patients up to 30 months post-RP-L301; first pediatric patient results suggest efficacy similar to adult cohort with initial greater than five-point increase in hemoglobin Sustained genetic correction observed in eight of 12 evaluable Fanconi Anemia patients, and phenotypic correction and concomitant hematologic stabilization observed in seven of 12 patients 12-42 months after... Read More
First clinical gene therapy program for PKP2-ACM, a devastating inherited heart disease affecting approximately 50,000 people in the U.S. and EU Robust preclinical proof of concept studies showed RP-A601 decreased arrhythmias and increased survival in the PKP2 knockout mouse model Initiating Phase 1 trial start-up activities and rapidly working towards first patient treatment CRANBURY, N.J. / May 09, 2023 / Business Wire /... Read More
Continued to advance leading pipeline of AAV cardiology and LV hematology assets; all 2023 milestones remain on track Updates on all four clinical programs and PKP2-ACM preclinical program to be presented at the 26 th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Mark White, MB.ChB, named Chief Medical Officer following more than 25 years at AstraZeneca; Jonathan Schwartz, M.D., appointed Chief Gene... Read More
CRANBURY, N.J. / May 03, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. ( NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference in Las... Read More
CRANBURY, N.J. / Apr 11, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Company management will participate in the 22nd Annual Needham Virtual Healthcare Conference and Chardan’s 7th Annual Genetic Medicines and Cell Therapy... Read More
Jonathan Schwartz, M.D., appointed Chief Gene Therapy Officer to enhance the Company’s focus on strategic application of gene therapy technologies to current and future therapeutic areas Mark White, MB.ChB, named Chief Medical Officer; Dr. White brings proven track record in late-stage development and commercialization with more than 25 years of experience at AstraZeneca CRANBURY, N.J. / Apr 04, 2023 / Business Wire / Rocket... Read More
CRANBURY, N.J. / Feb 07, 2023 / Business Wire / Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, the Company’s investigational... Read More
RP-A601 for Arrhythmogenic Cardiomyopathy due to PKP2 pathogenic variants (PKP2-ACM) represents meaningful commercial opportunity with estimated prevalence of 50,000 adults and children in the U.S. and EU; IND filing anticipated in Q2 2023 In support of Phase 2 pivotal study, latest positive Phase 1 data in Danon Disease recently shared with FDA demonstrate improvements in all biomarker and clinical endpoints across... Read More
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT. A live audio webcast of the... Read More
Based on ongoing FDA discussion, Rocket to pursue a biomarker-based composite endpoint for a single arm, open-label pivotal trial with a natural history comparator Initiation of initial component of global study anticipated in 1H’23 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with... Read More
Sustained genetic and phenotypic correction and concomitant hematologic stabilization observed in at least six of 10 evaluable FA patients between 12 and 36 months after RP-L102; a seventh patient potentially demonstrates engraftment and stabilization after 36 months Robust and sustained efficacy in both adult PKD patients at 24 months post-RP-L301 demonstrated by normalized hemoglobin and improved hemolysis parameters... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB